SIR and SIR Foundation

Awarded during the SIR 2026 Opening Plenary Session
Sunday, April 12, 10:30 a.m.– 12:00 p.m.

SIR Annual Dr. Charles T. Dotter Lecture

The Dr. Charles T. Dotter Lecture honors one of the founding fathers of interventional radiology and selection by the SIR president is based on extraordinary contributions to the field, dedicated service to the society and distinguished career achievements in interventional radiology. The Dotter lecture is made possible with funding from SIR Foundation.

Andrew Holden, MBChB, EBIR, ONZM

SIR Gold Medal recipients

The Gold Medal, the Society of Interventional Radiology's highest honor, is awarded not only for extraordinary service to SIR but to those who have dedicated their past and present talents to advancing the quality of medicine and patient care through the practice of interventional radiology.

Thierry de Baère, MD

Professor Thierry Jacques de Baère, MD, was head of the interventional radiology unit at Institut Gustave Roussy Cancer Center in Villejuif, France, where he had worked since 1991. Gustave Roussy is Europe’s largest cancer center. His clinical work was dedicated to minimal invasive therapy for treatment of liver, lung and kidney tumors, including intra-arterial therapies for primary and secondary liver tumors, and percutaneous ablation of liver tumors and lung tumors. Professor de Baère and his team had also pioneered and investigated preoperative portal vein embolization to hypertrophy unembolized parts of the liver. IO4IO (interventional radiology for immuno-oncology) was part of his new, very active research fields. He also actively studied robotic assistance for interventional oncology.

He was the author of over 450 peer-reviewed articles, resulting in over 35,000 citations. He was a reviewer for many cancer and interventional radiology journals and was a CardioVascular and Interventional Radiology section editor for interventional oncology from 2016–2022.
Professor de Baère was a member of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society for Medical Oncology (ESMO). He co-authored guidelines on hepatocellular carcinoma (HCC) and colorectal liverbmetastases with ESMO, European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer, and CIRSE. He was the principal investigator of several international studies on ablation, intra-arterial therapies, combined therapies and other innovative locoregional treatments.

Professor de Baère also served as a member of scientific program committees for several important global IR meetings including the World Congress of Interventional Oncology from 2006–2008 and 2011–2013; European Course of Interventional Oncology in 2008, 2014, 2016 and 2017; CIRSE 2008, 2009, 2013 and 2014; Global Embolization Symposium Technology from 2008–2012; and European Congress of Radiology from 2012–2013, among other meetings. He was a member of the CIRSE Foundation Advisory Council from 2008–2016 and a member of the CIRSE board from 2007–2009 and 2013–2015.

Scott Craig Goodwin, MD, MBA, FSIR, FACR

Scott Craig Goodwin, MD, MBA, FSIR, FACR, is internationally recognized for being one of the earliest providers pioneering uterine fibroid embolization (UFE). Starting in 1996 his group worked diligently on establishing the indications, safety and efficacy of the procedure and followed with the training/proctoring/advising of hundreds of physicians across the United States and the world so that the procedure would be widely available to women. He was the course director for the Society of Interventional Radiology’s (SIR’s) “Uterine Fibroid Embolization–New Advances in Women’s Health Care” national conferences.

He has given 148 national and international invited lectures and has 92 publications in peer-reviewed journals, authoring or co-authoring 15 first-in-kind UFE publications, including reports on the largest UFE study ever conducted. He was invited to write a review article on UFE that was published in the New England Journal of Medicine. He has over 5,000 citations (ResearchGate) and an estimated H-index of 38. In the Journal of Vascular and Interventional Radiology (JVIR) Celebrates 25 Years of Innovation 1990–2015 publication, two of Dr. Goodwin’s papers were listed as landmark publications in the field. In 2015, two of his groups’ papers were named as being cited in the top 100 cited publications in the radiology literature.

In 2023, SIR Foundation received a $500,000 donation in his name to study adenomyosis.

Dr. Goodwin graduated magna cum laude from University of California Los Angeles (UCLA) and went on to graduate in the top 15% of his medical class at Harvard. He completed diagnostic radiology and a fellowship in cardiovascular and interventional radiology at UCLA. He later earned an MBA from George Washington University, graduating first in his class.

He is a past president of SIR (2013–2014), and has held many national leadership roles, served as an American Board of Radiology (ABR) oral examiner (2005–2014), and received the ABR Lifetime Service Award. He has been reviewer for Radiology, JVIR, Fertility & Sterility, and Obstetrics & Gynecology, as well as several other journals. He has been repeatedly listed among America’s Top Doctors and is an Albert Nelson Marquis Lifetime Achievement Award recipient.

Dr. Goodwin has been instrumental in his roles in recognizing the importance of diversity, equity and inclusion. For example, while he was the chair of radiological sciences and vice president of the medical group at University of California Irvine (UCI) he recruited multiple talented accomplished women; when he left half of the section chiefs in his department were women. While on SIR’s operations council, he was instrumental in bringing two women into the leadership ranks, both of whom went on to become SIR presidents.

Dr. Goodwin retired in June 2025 and has maintained a volunteer appointment at the University of Arizona, where he still teaches, and is a professor emeritus at UCI. He continues to enjoy the great outdoors with his wife and best friend Suzie, especially backpacking, hiking and bicycling. His retirement is coincidental with the birth of his first grandson in Boston, where he has temporarily relocated to be near his growing family. He is very proud of his sons, one of whom is the CEO of his own company in Boston, and the other of whom is a software engineer at Mistral in Paris, France.

Lindsay Machan MD, FSIR

Lindsay Machan MD, FSIR, is an interventional radiologist at Vancouver Hospital and an associate professor in the department of Radiology at the University of British Columbia (UBC). He is also an associate member of the department of vascular surgery and the division of urology. Dr. Machan began his practice in 1989. In 1991, along with Peter Fry, MD, he established the first collaborative endovascular group in North America. In 1993, he started UBC’s interventional radiology fellowship program.

During his career, he performed several first-in-human procedures including fluoroscopically guided prostatic stent, removable metallic urethral stent, paclitaxel-coated stent and paclitaxel-coated vascular stent placements. His first-in-Canada procedures include percutaneous atherectomy (excisional and rotational), uterine fibroid embolization, ovarian vein embolization and aortic stent grafting, among others. In 2006, he and Bill Hunter, MD, shared the Manning Foundation Innovation Award for developing and commercializing the paclitaxel-coated stent. He was the primary investigator on a seminal, sham-controlled, double-blinded crossover study examining the viability of jugular angioplasty as a treatment for multiple sclerosis, which ultimately showed had no benefit over the sham procedure.

He was the co-editor of the 4th, 5th and 6th editions of Kandarpa’s Handbook of Interventional Procedures, the largest selling interventional radiology textbook. He has given over 700 invited lectures, including the Society of Interventional Radiology’s 2025 Charles T. Dotter Lecture. In addition to being a researcher, innovator and educator, Dr. Machan is also an entrepreneur, having founded two companies, Angiotech Pharmaceuticals and Ikomed Technologies.

A fellow of the Society of Interventional Radiology since 2000, Dr. Machan was honored with the SIR Foundation Leader in Innovation Award in 2015. He is also a distinguished fellow of the Cardiovascular and Interventional Radiological society of Europe and an honorary member of the Asia Pacific Society of Interventional Radiology. Dr. Machan is a founding member of the Canadian Association of Interventional Radiology (CAIR) and received CAIR’s Award for Career Achievement in 2020. In 2024, he was made an officer in the Order of Canada.

SIR Foundation Leader in Innovation Award

The Leader in Innovation Award recognizes and promotes innovation within interventional radiology, continuing IR’s historical innovative development that has revolutionized medicine over the last 40 years. The award acknowledges individuals who have conceptualized and implemented an idea that has had an advantageous impact on the practice of interventional radiology.